Otsuka and its partner Lundbeck snagged an FDA approval for Rexulti (brexpiprazole) to treat schizophrenia and as an add-on therapy for major depression, leaving the two companies prepping for an August launch into an increasingly crowded field.
ResearchKit, the technology Apple promises will transform the world's hundreds of millions of iPhones into handheld gatherers of clinical data, could become a viable tool in drug development, and two major drugmakers are working to integrated into clinical trials.
Catheters designed to deliver chemotherapy are often coated in silver to provide an antibacterial coating. But scientists at the Norwegian University of Science and Technology found that this silver actually breaks down chemotherapy drugs and can release a harmful gas, hydrogen fluoride in the process.
The rapid maturation of gene therapy technologies has galvanized a wide range of projects throughout industry and academia, and now a team of researchers from Harvard and Boston Children's Hospital believe they may have come up with a one-time treatment for a genetic cause of deafness.
Sanofi has widened its R&D net, recruiting 7 of the U.S.'s most-respected research institutions in hopes of ferreting out some new ideas in early-stage drug development.
Lawmakers in the House are expected to step up and cast their votes on the 21st Century Cures Act today, a big step toward once again shaking up the legal framework built to guide drug development in the U.S. while significantly boosting the amount of funding that flows to the NIH.
San Francisco's Global Blood Therapeutics, founded by Third Rock Ventures, is angling for a $115 million IPO to bankroll its work on an oral treatment for sickle cell disease.
Natera is lending its genetic testing technology to University College London for a lung cancer study, furthering the company's cancer R&D push after its recent IPO.
Billionaire entrepreneur Patrick Soon-Shiong further complicated his sprawling biotech empire with another joint venture, teaming up with frequent collaborator Sorrento Therapeutics to launch a new company focused on oncology.
Swedish contractor Recipharm has deepened its ties with partner Pharmanest, taking up a 25% stake in the biotech as the two collaborate on a pain drug.